A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
Purpose
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
Condition
- Progressive Pulmonary Fibrosis
Eligibility
- Eligible Ages
- Over 21 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Diagnosis of interstitial lung disease (ILD) with features consistent with progressive ILD within 24 months prior to screening, and ≥ 10% extent of fibrosis on screening high-resolution computed tomography (HRCT). - If on pirfenidone or nintedanib, participants must have been on a stable dose for at least 90 days prior to screening. - If not currently on pirfenidone or nintedanib, participants must not have received either of these medications within 28 days prior to screening. - Mycophenolate mofetil (MMF), mycophenolic acid (MA), azathioprine (AZA), and Tacrolimus are permitted provided that the participant is on a stable dose for at least 90 days prior to screening. If not currently on MMF, MA, AZA, or tacrolimus, participants must not have taken these medications within 28 days prior to screening. - Traditional disease-modifying antirheumatic drug (DMARDs) (eg. Methotrexate, leflunomide, sulfasalazine, or hydroxychloroquine) are permitted provided that the participant is on a stable dose for at least 90 days prior to screening. If not currently on traditional DMARD, participants must not have taken these medications within 28 days prior to screening. - Biologic DMARDs (eg. TNF blockers and IL-1 inhibitors) and Janus kinase inhibitors (JAK inhibitors eg. tofacitinib, upadacitinib) are permitted provided that the participant is on a stable dose for at least 90 days prior to screening. If not currently on Biologic DMARD or JAK inhibitor, participants must not have taken these medications within 28 days prior to screening. - Women who are of childbearing potential must have a highly effective form of contraception and must provide a negative urine/serum pregnancy test. - Men who are sexually active with women of childbearing potential agree to use male barrier contraception.
Exclusion Criteria
- Idiopathic pulmonary fibrosis with usual interstitial pneumonia (UIP) verification at screening. - History of stroke or transient ischemic attack within 3 months prior to screening. - Participants who exhibit symptoms of heart failure at rest. - Participants who have a current malignancy; a previous malignancy with less than 2 years free of recurrence; and a biopsy that is suspicious for malignancy and the possibility of malignancy cannot be reasonably excluded following additional clinical, laboratory, or other diagnostic evaluations. - Use of systemic corticosteroids equivalent to prednisone > 15 mg/day is not allowed within 4 weeks prior to screening and during the study. - Other protocol-defined Inclusion/Exclusion criteria apply.
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Experimental BMS-986278 Dose 1 |
|
|
Experimental BMS-986278 Dose 2 |
|
|
Placebo Comparator BMS-986278 Placebo |
|
Recruiting Locations
Birmingham 4049979, Alabama 4829764 35294
Tejaswini Kulkarni, Site 0046
617-480-7076
Phoenix 5308655, Arizona 5551752 85013-4220
Rajat Walia, Site 0314
602-406-4000
La Jolla 5363943, California 5332921 92037-1027
Jacqueline Chang, Site 0336
858-824-5404
Los Angeles 5368361, California 5332921 90033-5313
Toby Maher, Site 0212
323-865-9854
Los Angeles 5368361, California 5332921 90095-3075
John Belperio, Site 0019
310-968-6324
Orange 5379513, California 5332921 92868-3201
Huawei Dong, Site 0366
714-456-6776
Sacramento 5389489, California 5332921 95817
Timothy Albertson, Site 0341
916-734-3650
San Francisco 5391959, California 5332921 94143-2202
Jeffrey Golden, Site 0015
415-353-2060
Stanford 5398563, California 5332921 94305
Rishi Raj, Site 0352
650-725-8083
Aurora 5412347, Colorado 5417618 80045
Joyce Lee, Site 0321
303-724-6109
Denver 5419384, Colorado 5417618 80206
Michael Mohning, Site 0376
720-945-8608
New Haven 4839366, Connecticut 4831725 06510
Mridu Gulati, Site 0211
203-785-4196
Stamford 4843564, Connecticut 4831725 06904
Caroline Gulati, Site 0418
203-785-2104
Newark 4143861, Delaware 4142224 19713-1337
Renee Dixon, Site 0067
302-623-7600
Washington D.C. 4140963, District of Columbia 4138106 20007-2113
Cristina Reichner, Site 0354
202-444-0895
Brandon 4148757, Florida 4155751 33511-5706
Rafael Martinez, Site 0195
813-413-7218
Celebration 4150394, Florida 4155751 34747-1818
Fortune Alabi, Site 0380
877-352-5864
Clearwater 4151316, Florida 4155751 33765
Francis Averill, Site 0013
727-210-4606
DeBary 4152926, Florida 4155751 32713-1817
Kwabena Ayesu, Site 0396
386-668-4202
Gainesville 4156404, Florida 4155751 32608
Faye Pais, Site 0036
35254860001076298
Gainesville 4156404, Florida 4155751 32610
Christopher Harden, Site 0193
352-284-5069
Loxahatchee Groves 4162948, Florida 4155751 33411
Neal Warshoff, Site 0073
561-795-1022
Pensacola 4168228, Florida 4155751 32503
Peter Bercz, Site 0452
850-477-7900
St. Petersburg 4171563, Florida 4155751 33704
Warren Abel, Site 0389
727-822-6661
Tampa 4174757, Florida 4155751 33601-1289
Debabrata Bandyopadhyay, Site 0316
813-844-7137
Atlanta 4180439, Georgia 4197000 30322-1013
Srihari Veeraraghavan, Site 0070
404-778-5736
Dublin 4192205, Georgia 4197000 31021-2561
Vishal Agrawal, Site 0368
478-272-3209
Chicago 4887398, Illinois 4896861 60611
Bradford Bemiss, Site 0435
708-216-0160
Chicago 4887398, Illinois 4896861 60637-1447
Ayodeji Adegunsoye, Site 0023
205-585-9948
Maywood 4901514, Illinois 4896861 60153-3328
Daniel Dilling, Site 0082
Iowa City 4862034, Iowa 4862182 522242-1009
Nabeel Hamzeh, Site 0080
319-356-8343
Kansas City 4273837, Kansas 4273857 66103-2937
Mark Hamblin, Site 0049
Louisville 4299276, Kentucky 6254925 40218-2497
John McConnell, Site 0361
502-587-8000
Baltimore 4347778, Maryland 4361885 21201-1544
Edward Britt, Site 0305
410-328-8141
Boston 4930956, Massachusetts 6254926 02114-2621
Barry Shea, Site 0404
617-726-1721
Ann Arbor 4984247, Michigan 5001836 48109-5000
Jamie Sheth, Site 0207
Grand Rapids 4994358, Michigan 5001836 49546-8293
Gayathri Sathiyamoorthy, Site 0050
616-267-9313
Minneapolis 5037649, Minnesota 5037779 55455-4800
Hyun Kim, Site 0384
612-624-0999
Chesterfield 4381072, Missouri 4398678 63017
Neil Ettinger, Site 0004
314-682-3653
St Louis 4407066, Missouri 4398678 63110-1010
Mary Clare McGregor, Site 0223
314-362-9919
Reno 5511077, Nevada 5509151 89502-1576
Farah Kassamali Madhani-Lovely, Site 0525
775-982-4100
Mount Kisco 5127744, New York 5128638 10549-3417
Bushra Ayad Mina, Site 0068
212-794-2800
New York 5128581, New York 5128638 10029-6574
Maria Padilla, Site 0357
212-241-5656
Durham 4464368, North Carolina 4482348 27710
Aparna Swaminathan, Site 0428
610-442-9029
Wilmington 4499379, North Carolina 4482348 28401-7307
Hector Sanchez, Site 0392
910-815-6108
Winston-Salem 4499612, North Carolina 4482348 27103
Reginald Fowler, Site 0325
336-659-8414
Cincinnati 4508722, Ohio 5165418 45267
Nishant Gupta, Site 0419
513-558-4831
Cleveland 5150529, Ohio 5165418 44106
Maroun Matta, Site 0186
216-844-8447
Columbus 4509177, Ohio 5165418 43201
Derrick Herman, Site 0209
330-554-9628
Toledo 5174035, Ohio 5165418 43608-2603
Vinod Khatri, Site 0343
419-251-4919
Oklahoma City 4544349, Oklahoma 4544379 73104-5417
Jad Kebbe, Site 0198
405271617354612
Tulsa 4553433, Oklahoma 4544379 74133
Hassan Abouhouli, Site 0008
918-307-5490
Portland 5746545, Oregon 5744337 97239-3011
Daniel Seifer, Site 0037
503-494-1620
Hershey 5193342, Pennsylvania 6254927 17033-2360
Rebecca Bascom, Site 0205
717-531-2925
Philadelphia 4560349, Pennsylvania 6254927 19104-5161
Kathryn Flack, Site 0334
Philadelphia 4560349, Pennsylvania 6254927 19107-5109
Ross Summer, Site 0348
215-955-5161
Philadelphia 4560349, Pennsylvania 6254927 19140-5103
Gerard Criner, Site 0196
215-707-8113
Wynnewood 5220230, Pennsylvania 6254927 19096
Eliot Friedman, Site 0364
610-642-3796
Anderson 4569298, South Carolina 4597040 29621
Abhijit Raval, Site 0531
423-741-6106
Charleston 4574324, South Carolina 4597040 29425
Timothy Whelan, Site 0071
843-792-3167
Greenville 4580543, South Carolina 4597040 29615
Luis De La Cruz, Site 0373
864-770-0890
Nashville 4644585, Tennessee 4662168 37204
Margaret Salisbury, Site 0363
314-608-6188
Dallas 4684888, Texas 4736286 75235-5351
Corey Kershaw, Site 0024
214-645-7108
Dallas 4684888, Texas 4736286 75246
Yolanda Mageto, Site 0317
000-000-0000
Houston 4699066, Texas 4736286 77030-4202
Ivan Rosas, Site 0028
713-798-8842
Houston 4699066, Texas 4736286 77030
Rodeo Abrencillo, Site 0041
713-500-6851
McKinney 4710178, Texas 4736286 75069
Shahrukh Kureishy, Site 0221
972-838-1892
San Antonio 4726206, Texas 4736286 78229-4404
Anoop Nambiar, Site 0217
Salt Lake City 5780993, Utah 5549030 84108
Mary Beth Scholand, Site 0014
801-581-5811
Burlington 5234372, Vermont 5242283 05401
Ena Gupta, Site 0504
802-847-1158
Richmond 4781708, Virginia 6254928 23298-5002
Apostolos Perelas, Site 0414
215-760-2976
Everett 5793933, Washington 5815135 98208-6526
Tomasz Ziedalski, Site 0190
425-252-1118
Seattle 5809844, Washington 5815135 98195
Chi Hung, Site 0043
206-897-5377
Guaynabo 4565119, PR, Puerto Rico 968
Alvaro Aranda, Site 0214
7873978809
More Details
- NCT ID
- NCT06025578
- Status
- Recruiting
- Sponsor
- Bristol-Myers Squibb
Study Contact
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com855-907-3286
Clinical.Trials@bms.com